Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar;18(2):149-66.
doi: 10.1007/s10741-012-9313-3.

Diabetic cardiomyopathy: pathophysiology and clinical features

Affiliations
Review

Diabetic cardiomyopathy: pathophysiology and clinical features

Takayuki Miki et al. Heart Fail Rev. 2013 Mar.

Abstract

Since diabetic cardiomyopathy was first reported four decades ago, substantial information on its pathogenesis and clinical features has accumulated. In the heart, diabetes enhances fatty acid metabolism, suppresses glucose oxidation, and modifies intracellular signaling, leading to impairments in multiple steps of excitation-contraction coupling, inefficient energy production, and increased susceptibility to ischemia/reperfusion injury. Loss of normal microvessels and remodeling of the extracellular matrix are also involved in contractile dysfunction of diabetic hearts. Use of sensitive echocardiographic techniques (tissue Doppler imaging and strain rate imaging) and magnetic resonance spectroscopy enables detection of diabetic cardiomyopathy at an early stage, and a combination of the modalities allows differentiation of this type of cardiomyopathy from other organic heart diseases. Circumstantial evidence to date indicates that diabetic cardiomyopathy is a common but frequently unrecognized pathological process in asymptomatic diabetic patients. However, a strategy for prevention or treatment of diabetic cardiomyopathy to improve its prognosis has not yet been established. Here, we review both basic and clinical studies on diabetic cardiomyopathy and summarize problems remaining to be solved for improving management of this type of cardiomyopathy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Proposed mechanisms of contractile dysfunction by diabetes. EC coupling excitation–contraction coupling, APD action potential duration, SR sarcoplasmic reticulum, FFA free fatty acid, CFR coronary flow reserve, SMC smooth muscle cell
Fig. 2
Fig. 2
Proposed mechanisms of diabetes-induced increase in susceptibility of the myocardium to ischemia/reperfusion-induced infarction. mPTP mitochondrial permeability transition pore, SMC smooth muscle cell
Fig. 3
Fig. 3
Examples of Doppler echocardiography in a healthy subject and a T2DM patient. Transmitral flow patterns are shown for a healthy subject (a) and a T2DM patient (b). Peak velocities during early diastole (E) and late diastole (A) are shown. E/A ratios are 2.2 and 0.6 in a, b, respectively. c, d show tissue Doppler imaging, with positioning of sample volume at the septal mitral annulus, in a healthy subject and a T2DM patient, respectively. The diabetic patient (d) had lower peak velocities during systole (S′) and early diastole (E′) (7.5 and 6.0 cm/s, respectively) than those in the healthy subject (c 8.5 and 15.0 cm/s, respectively)
Fig. 4
Fig. 4
Tissue Doppler-derived strain and strain rate of the left ventricle. a, b show strain and strain rates, respectively, in a normal control. Ss septal peak strain, SRs strain rate in systole, SRe strain rate in early diastole. c shows comparison of LV strain rates in normal controls (white bars, n = 15) and normotensive T2DM patients without coronary artery disease (black bars, n = 15). *P < 0.05 versus control. (S. Yuda, unpublished data)

References

    1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40. - PubMed
    1. Sobel BE. Optimizing cardiovascular outcomes in diabetes mellitus. Am J Med. 2007;120(Suppl 2):S3–S11. - PubMed
    1. Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes. 2004;53(Suppl 3):S39–S47. - PubMed
    1. From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, Rodeheffer RJ, Roger VL. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006;119:591–599. - PubMed
    1. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care. 2003;26:2433–2441. - PubMed

Publication types

MeSH terms